Connect with us

Technology

Ceragon Reports 20% Growth in the Fourth Quarter of 2023; Exceeds Full-Year 2023 Guidance

Published

on

Company Guides for Double Digit Growth; Targeting to Further Penetrate Private Network Markets  

ROSH HA’AIN, Israel, Feb. 20, 2024 /PRNewswire/ — Ceragon Networks Ltd. (NASDAQ: CRNT), the global innovator and leading solutions provider of 5G wireless transport, today reported its financial results for the fourth quarter and full year period ended December 31, 2023.

Q4 2023 Financial Highlights:

Revenues of $90.4 million, up 20% year-over-yearSiklu acquisition, which closed on December 4, 2023, contributed modestly to quarterly revenue, in-line with expectationsOperating income of $4.2 million on a GAAP basis, or $7.8 million on a non-GAAP basisNet loss of $(1.2) million on a GAAP basis, and net income of $3.7 million on a non-GAAP basisEPS of $(0.01) per diluted share on a GAAP basis, or $0.04 per diluted share on a non-GAAP basis

FY 2023 Financial Highlights:

Revenues of $347.2 million, up 18% year-over-year, exceeding full-year guidanceCeragon would have achieved the higher-end of its full-year revenue guidance even without contribution from SikluOperating income of $21.2 million on a GAAP basis, or a record $29.0 million on a non-GAAP basisNet income of $6.2 million on a GAAP basis, and $16.7 million on a non-GAAP basisEPS of $0.07 per diluted share on a GAAP basis, or $0.20 per diluted share on a non-GAAP basis

Q4 2023 Business Highlights:

Completed the acquisition of Siklu, expanding presence in North America and augmenting Ceragon’s offering in the Fixed Wireless Access marketNorth America:Continued strong bookings, supported by demand for 5G capabilities from Tier-1 customers and increased footprint with private network customersFourth consecutive quarter of revenues exceeding $20 millionIndia:Continued strong bookings, including initial orders from the approximately $150 million project from global integrator, in support of a network modernization project for a Tier 1 OperatorStrongest region in terms of revenue, with record quarterly revenue since Q2 2018

Doron Arazi, CEO, commented: “Ceragon delivered revenue growth that exceeded our full-year outlook and record full-year non-GAAP operating income. We are encouraged with the recent acquisition of Siklu bolstering our position in the fastest-growing verticals of our market, and continued strong demand for our solutions. In our two key markets, North America and India, we continue to experience strong demand and we remain optimistic that these markets will continue to drive our growth. During 2023, we expanded our presence in the private network market, establishing a scalable foundation for continued growth.”

“We have also reached the point where we can unlock meaningful operating leverage,” continued Arazi. “Our non-GAAP gross margins in the quarter exceeded 35%, and we delivered record levels of annual non-GAAP operating profit. Ceragon has also generated significant full-year free cash flow, enabling us to continue enhancing our product portfolio while growing our profitability.” 

Primary Fourth Quarter 2023 Financial Results:

Revenues were $90.4 million, up 20% from $75.5 million in Q4 2022 and up 3.6% from $87.3 million in Q3 2023.

Gross profit was $31.1 million, giving us a gross margin of 34.4%, compared to gross margin of 32.5% in Q4 2022 and 34.7% in Q3 2023. 

Operating income was $4.2 million compared to $(10.6) million for Q4 2022 and $6.7 million for Q3 2023. The fourth quarter of 2023 included expenses related to the acquisition of Siklu and the consolidation of Siklu results since closing on December 4, 2023. 

Net income (loss) was $(1.2) million, or $(0.01) per diluted share, compared to $(15.0) million, or $(0.18) per diluted share for Q4 2022 and $3.4 million, or $0.04 per diluted share for Q3 2023.

Non-GAAP results were as follows: Gross margin was 35.1%, operating profit was $7.8 million, and net income of $3.7 million, or $0.04 per diluted share. Management continues to expect Siklu to be accretive to non-GAAP earnings by the second-half of 2024. 

Primary Full-Year 2023 unaudited Financial Results:

Revenues were $347.2 million, up 18% from $295.2 million in 2022. 

Gross profit was $119.9 million, giving us a gross margin of 34.5%, compared to a gross margin of 31.5% in 2022. 

Operating income (loss) was $21.2 million compared to $(10.9) million for 2022. 

Net income (loss) was $6.2 million, or $0.07 per diluted share, compared to $(19.7) million, or $(0.23) per diluted share for 2022.

Non-GAAP results were as follows: Gross margin was 34.8%, operating profit was $29.0 million, and net income was $16.7 million, or $0.20 per diluted share.

Balance Sheet

Cash and cash equivalents were $28.2 million at December 31, 2023, compared to $22.9 million at December 31, 2022.

For a reconciliation of GAAP to non-GAAP results, see the attached tables.

Revenue Breakout by Geography:

Q4 2023

India

34 %

North America    

27 %

Latin America    

13 %

Europe     

11 %

Africa    

8 %

APAC   

7 %

Outlook
For 2024, management expects:

Revenue of $385 million to $405 million, representing growth of 11% to 17% compared to 2023 revenue. This guidance includes the contribution from Siklu, which was acquired in December 2023.Non-GAAP operating margins are targeted to be at least 10% at the mid-point of the revenue guidance.As a result, management expects increased non-GAAP profit and positive free cash flow for the full year of 2024.

Conference Call

The Company will host a Zoom web conference today at 8:30 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. 

Investors are invited to register by clicking here. All relevant information will be sent upon registration. 

If you are unable to join the live call, a replay will be available on our website at www.ceragon.com within 24 hours after the call. 

About Ceragon Networks

Ceragon Networks Ltd. (NASDAQ: CRNT) is the global innovator and leading solutions provider of 5G wireless transport. We help operators and other service providers worldwide increase operational efficiency and enhance end customers’ quality of experience with innovative wireless backhaul and fronthaul solutions. Our customers include service providers, public safety organizations, government agencies and utility companies, which use our solutions to deliver 5G & 4G broadband wireless connectivity, mission-critical multimedia services, stabilized communications, and other applications at high reliability and speed.

Ceragon’s unique multicore technology and disaggregated approach to wireless transport provides highly reliable, fast to deploy, high-capacity wireless transport for 5G and 4G networks with minimal use of spectrum, power, real estate, and labor resources. It enables increased productivity, as well as simple and quick network modernization, positioning Ceragon as a leading solutions provider for the 5G era. We deliver a complete portfolio of turnkey end-to-end AI-based managed and professional services that ensure efficient network rollout and optimization to achieve the highest value for our customers. Our solutions are deployed by more than 400 service providers, as well as more than 800 private network owners, in more than 150 countries. For more information please visit: www.ceragon.com.

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON ® is a trademark of Ceragon Networks Ltd., registered in various countries. Other names mentioned are owned by their respective holders.

Safe Harbor

This press release contains statements that constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Ceragon’s management about Ceragon’s business, financial condition, results of operations, micro and macro market trends and other issues addressed or reflected therein. Examples of forward-looking statements include, but are not limited to, statements regarding: projections of demand, revenues, net income, gross margin, capital expenditures and liquidity, competitive pressures, order timing, supply chain and shipping, components availability; growth prospects, product development, financial resources, cost savings and other financial and market matters. You may identify these and other forward-looking statements by the use of words such as “may”, “plans”, “anticipates”, “believes”, “estimates”, “targets”, “expects”, “intends”, “potential” or the negative of such terms, or other comparable terminology, although not all forward-looking statements contain these identifying words.

Although we believe that the projections reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations therefrom will not be material. Such forward-looking statements involve known and unknown risks and uncertainties that may cause Ceragon’s future results or performance to differ materially from those anticipated, expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the effects of global economic trends, including recession, rising inflation, rising interest rates, commodity price increases and fluctuations, commodity shortages and exposure to economic slowdown; The effects of the evolving nature of the war situation in Israel, including in Gaza with the Hamas and in Lebanon with the Hezbollah and the related evolving regional conflict, including without limitation, the Houti attacks on marine vessels; risks associated with delays in the transition to 5G technologies and in the 5G rollout; the risks associated with the introduction of new products to the market, including but not limited to potential delays, unexpected costs, regulatory hurdles and potential technical flaws; risks relating to the concentration of our business on a limited number of large mobile operators and the fact that the significant weight of their ordering, compared to the overall ordering by other customers, coupled with inconsistent ordering patterns, could negatively affect us; risks resulting from the volatility in our revenues, margins and working capital needs; disagreements with tax authorities regarding tax positions that we have taken could result in increased tax liabilities;  the high volatility in the supply needs of our customers, which from time to time lead to delivery issues and may lead to us being unable to timely fulfill our customer commitments; risks associated with inaccurate forecasts or business changes, which may expose us to inventory-related losses on inventory purchased by our contract manufacturers and other suppliers, to increased expenses should unexpected production ramp up be required, or to write off to parts of our inventory, which would increase our cost of revenues; potential adverse reactions or changes to business relationships resulting from the completion of the transaction with Siklu, and ongoing or potential litigations or disputes, incidental to the conduct of Siklu’s business and other risks related to the integration of Siklu’s business into Ceragon business; disagreements with tax authorities regarding tax positions that we have taken could result in increased tax liabilities and such other risks, uncertainties and other factors that could affect our results of operation, as further detailed in Ceragon’s most recent Annual Report on Form 20-F, as published on May 1, 2023, as well as other documents that may be subsequently filed by Ceragon from time to time with the SEC. 

We caution you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Ceragon does not assume any obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release unless required by law.

While we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, any forward-looking statements represent Ceragon’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Ceragon does not assume any obligation to update any forward-looking statements unless required by law.

The results reported in this press-release are preliminary and unaudited results, and investors should be aware of possible discrepancies between these results and the audited results to be reported, due to various factors.

Ceragon’s public filings are available on the Securities and Exchange Commission’s website at www.sec.gov and may also be obtained from Ceragon’s website at www.ceragon.com

Ceragon Investor & Media Contact:

Rob Fink 
FNK IR
Tel. 1+646-809-4048
crnt@fnkir.com 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, U.S. dollars in thousands, except share and per share data)

(Unaudited)

Three months ended

December 31,

Year ended

December 31,

2023

2022

2023

2022

Revenues

$     90,359

$    75,531

$  347,179

$  295,173

Cost of revenues

59,296

50,999

227,310

202,110

Gross profit

31,063

24,532

119,869

93,063

Operating expenses:

Research and development, net

9,070

8,080

32,274

29,690

Sales and Marketing

10,544

8,998

40,577

35,795

General and administrative

6,445

17,826

23,793

34,295

Restructuring and related charges

897

Acquisition and integration-related charges

835

1,118

Other operating expenses (*)

249

4,220

Total operating expenses

26,894

35,153

98,659

104,000

Operating income (loss)

4,169

(10,621)

21,210

(10,937)

Financial expenses and others, net

3,402

3,012

8,468

6,306

Income (loss) before taxes

767

(13,633)

12,742

(17,243)

Taxes on income

1,970

1,385

6,522

2,446

Net income (loss)

$     (1,203)

$   (15,018)

$      6,220

$   (19,689)

Basic net income (loss) per share

$       (0.01)

$       (0.18)

$        0.07

$       (0.23)

Weighted average number of shares used in computing  basic net income (loss) per share

85,054,173

84,347,548

84,617,774

84,132,982

Diluted net income (loss) per share

$       (0.01)

$       (0.18)

$        0.07

$       (0.23)

Weighted average number of shares used in computing diluted net income (loss) per share

85,054,173

84,347,548

85,482,626

84,132,982

(*) Hostile attempt related costs.

                                  

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

December 31,

2023

December 31,

2022

ASSETS

Unaudited

Audited

CURRENT ASSETS:

Cash and cash equivalents

$            28,237

$           22,948

Trade receivables, net

104,321

100,034

Other accounts receivable and prepaid expenses

16,571

15,756

Inventories

68,811

72,009

Total current assets

217,940

210,747

NON-CURRENT ASSETS:

   Severance pay and pension fund

4,985

4,633

   Property and equipment, net

30,659

29,456

   Operating lease right-of-use assets

18,837

17,962

   Intangible assets, net

16,401

8,208

   Goodwill

7,749

    Other non-current assets

1,954

18,312

Total non-current assets

80,585

78,571

Total assets

$         298,525

$         289,318

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables

67,032

67,384

Deferred revenues

5,507

3,343

Short-term loans

32,600

37,500

Operating lease liabilities

3,889

3,745

Other accounts payable and accrued expenses

23,925

20,864

Total current liabilities

132,953

132,836

LONG-TERM LIABILITIES:

Accrued severance pay and pension

9,399

9,314

Deferred revenues

670

11,545

Other long-term payables

7,768

2,653

Operating lease liabilities

13,716

13,187

Total long-term liabilities

31,553

36,699

SHAREHOLDERS’ EQUITY:

Share capital:

     Ordinary shares

222

224

Additional paid-in capital

437,161

432,214

Treasury shares at cost

(20,091)

(20,091)

Other comprehensive loss

(8,085)

(11,156)

Accumulated deficit

(275,188)

(281,408)

Total shareholders’ equity

134,019

119,783

Total liabilities and shareholders’ equity

$        298,525

$          289,318

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited, U.S. dollars, in thousands)

(Unaudited)

Three months ended

December 31,

Year ended

December 31,

2023

2022

2023

2022

Cash flow from operating activities:

Net income (loss)

$       (1,203)

$      (15,018)

$        6,220

$     (19,689)

Adjustments to reconcile net income (loss) to net cash
  provided by (used in) operating activities:

Depreciation and amortization

2,466

2,622

9,967

11,040

Loss from sale of property and equipment, net

61

20

Stock-based compensation expense

938

958

3,964

3,560

Increase (decrease) in accrued severance pay and pensions, net

88

245

(267)

(445)

Decrease (increase) in trade receivables, net

1,856

15,942

(2,370)

18,428

Decrease (increase) in other accounts receivable and prepaid
  expenses (including other long term assets)

15,085

1,414

16,994

(345)

Decrease (increase) in inventory

4,681

(7,845)

6,303

(11,155)

Decrease in operating lease right-of-use assets

794

845

3,781

3,571

Increase in trade payables

(1,121)

(5,191)

(1,847)

(2,018)

Increase (decrease) in other accounts payable and accrued
  expenses (including other long term liabilities)

(2,720)

(2,190)

1,677

(4,154)

Decrease in operating lease liability

(73)

(779)

(4,034)

(5,937)

Increase (decrease) in deferred revenues

(9,830)

494

(9,562)

2,229

Net cash provided by (used in) operating activities

$      10,961

$        (8,503)

$       30,887

$      (4,895)

Cash flow from investing activities:

Purchases of property and equipment, net

(2,548)

(1,432)

(9,955)

(10,464)

Purchases of intangible assets

(661)

(697)

(2,944)

(1,957)

Payments made in connection with business acquisitions, net
  of acquired cash

(7,971)

(7,971)

Net cash used in investing activities

$      (11,180)

$          (2,129)

$     (20,870)

$     (12,421)

Cash flow from financing activities:

Proceeds from exercise of options

9

39

410

Proceeds from (repayments of) bank credits and loans, net

(5,600)

7,600

(4,900)

22,700

Net cash provided by (used in) financing activities

$        (5,591)

$           7,600

$        (4,861)

$      23,110

Translation adjustments on cash and cash equivalents

$              81

$                16

$            133

$             75

Increase (decrease) in cash and cash equivalents

$        (5,729)

$          (3,016)

$         5,289

$        5,869

Cash and cash equivalents at the beginning of the period

33,966

25,964

22,948

17,079

Cash and cash equivalents at the end of the period

$        28,237

$          22,948

$        28,237

$      22,948

 

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS

(U.S. dollars in thousands, except share and per share data

(Unaudited)

Three months ended

         Year ended

December 31,

December 31,

2023

2022

2023

2022

GAAP cost of revenues

$

59,296

$

50,999

$

227,310

$

202,110

Stock-based compensation expenses

(115)

(169)

(482)

(587)

Changes in indirect tax positions

(279)

(3)

(281)

Amortization of acquired intangible assets

(57)

(57)

Excess cost on acquired inventory in business combination*

(525)

(525)

Non-GAAP cost of revenues

$

58,599

$

50,551

$

226,243

$

201,242

GAAP gross profit

$

31,063

$

24,532

$

119,869

$

93,063

Stock-based compensation expenses

115

169

482

587

Changes in indirect tax positions

279

3

281

Amortization of acquired intangible assets

57

57

Excess cost on acquired inventory in business combination

525

525

Non-GAAP gross profit

$

31,760

$

24,980

$

120,936

$

93,931

GAAP Research and development expenses

$

9,070

$

8,080

$

32,274

$

29,690

Stock-based compensation expenses

(156)

(217)

(828)

(405)

Loss from termination of joint development agreement

(1,199)

(1,199)

Non-GAAP Research and development expenses

$

7,715

$

7,863

$

30,247

$

29,285

GAAP Sales and Marketing expenses

$

10,544

$

8,998

$

40,577

$

35,795

Stock-based compensation expenses

(320)

(393)

(1,416)

(1,355)

Amortization of acquired intangible assets

(49)

(49)

Non-GAAP Sales and Marketing expenses

$

10,175

$

8,605

$

39,112

$

34,440

GAAP General and Administrative expenses

$

6,445

$

17,826

$

23,793

$

34,295

Stock-based compensation expenses

(347)

(179)

(1,238)

(1,213)

Retired CEO compensation

96

Non-GAAP General and Administrative expenses

$

6,098

$

17,647

$

22,555

$

33,178

GAAP Restructuring and related charges

$

$

$

897

$

Restructuring and related charges

(897)

Non-GAAP restructuring and related charges

$

$             –

$               –

$               –

GAAP Acquisition and integration-related charges

$

835

$

$

1,118

$

Acquisition and integration-related

(835)

(1,118)

Non-GAAP acquisition and integration-related charges

$

$             –

$               –

$               –

GAAP Other operating expenses

$

$

249

$

$

4,220

Hostile attempt related costs

(249)

(4,220)

Non-GAAP other operating expenses

$

$             –

$               –

$               –

 

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS

(U.S. dollars in thousands, except share and per share data

(Unaudited)

Three months ended

Year Ended

December 31,

December 31,

2023

2022

2023

2022

GAAP operating income (loss)                        

$

4,169

$

(10,621)

$

21,210

$

(10,937)

Stock-based compensation expenses

938

958

3,964

3,560

Changes in indirect tax positions

279

3

281

Amortization of acquired intangible assets

106

106

Excess cost on acquired inventory in business combination*

525

525

Loss from termination of joint development agreement

1,199

1,199

Retired CEO compensation

(96)

Hostile attempt related costs

249

4,220

Restructuring and other charges

897

Acquisition and integration-related charges

835

1,118

Non-GAAP operating income (loss)

$

7,772

$

(9,135)

$

29,022

$

(2,972)

GAAP financial expenses and others, net

$

3,402

$

3,012

$

8,468

$

6,306

Non-cash revaluation associated with acquisition

(110)

(110)

Leases – financial income (expenses)

(754)

(154)

253

2,278

Non-GAAP financial expenses & others, net

$

2,538

$

2,858

$

8,611

$

8,584

GAAP Tax expenses

$

1,970

$

1,385

$

6,522

$

2,446

Noncash tax adjustments

(478)

(851)

(2,851)

(1,278)

Non-GAAP Tax expenses

$

1,492

$

534

$

3,671

$

1,168

 

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS

(U.S. dollars in thousands, except share and per share data

(Unaudited)

Three months ended

Year Ended

December 31,

December 31,

2023

2022

2023

2022

GAAP net income (loss)

$

(1,203)

$

(15,018)

$

6,220

$

(19,689)

Stock-based compensation expenses

938

958

3,964

3,560

Changes in indirect tax positions

279

3

281

Amortization of acquired intangible assets

106

106

Excess cost on acquired inventory in business combination*

525

525

Loss from termination of joint development agreement

1,199

1,199

Retired CEO compensation

(96)

Hostile attempt related costs

249

4,220

Restructuring and other charges

897

Acquisition and integration-related charges

835

1,118

Non-cash revaluation associated with acquisition

110

110

Non-cash tax adjustments

478

851

2,851

1,278

Leases – financial income (expenses)

754

154

(253)

(2,278)

Non-GAAP net income (loss) 

$

3,742

$

(12,527)

$

16,740

$

(12,724)

GAAP Basic net income (loss) per share

$

(0.01)

$

(0.18)

$

0.07

$

(0.23)

GAAP Diluted net income (loss) per share

$

(0.01)

$

(0.18)

$

0.07

$

(0.23)

Non GAAP Diluted net income (loss) per share (**)

$

0.04

$

(0.15)

$

0.20

$

(0.15)

(*) Consists of charges to cost of revenues for the difference between the fair value of acquired inventory in business combination, which was recorded at fair value, and the actual cost of this inventory, which impacts the Company’s gross profit.
(**) Weighted average number of shares used in computing diluted net income (loss) per share is the same as in GAAP

Logo: https://mma.prnewswire.com/media/1704355/Ceragon_Networks_Ltd_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/ceragon-reports-20-growth-in-the-fourth-quarter-of-2023-exceeds-full-year-2023-guidance-302066012.html

SOURCE Ceragon Networks Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Melanie Siewert, Chief Marketing Officer at LHH, Joins the Exceptional Women Alliance (EWA)

Published

on

By

LOS ANGELES, May 8, 2026 /PRNewswire/ — The Exceptional Women Alliance (EWA) proudly welcomes Melanie Siewert, Chief Marketing Officer at LHH, into its distinguished community of influential women leaders. A seasoned global marketing executive, Siewert brings more than 20 years of experience transforming brands, building high-performing teams, and driving measurable growth across both B2B and B2C industries.

As Chief Marketing Officer of LHH, Siewert leads global marketing strategy across brand, demand generation, and customer experience. She plays a critical role in aligning marketing with business objectives and fostering strong collaboration with sales to enhance organizational performance and accelerate growth. Her leadership has been instrumental in shaping a modern, customer-centric brand and building a marketing function designed to deliver consistent, high-impact results across a complex global enterprise.

Throughout her career, Siewert has held senior leadership roles at prominent organizations including Truist Financial, Worldpay, Equifax, Whirlpool Corporation, and JPMorgan Chase. She is widely recognized for guiding enterprise brand strategy, leading complex mergers, scaling marketing operations, and delivering measurable gains in pipeline, revenue, and digital adoption.

Siewert’s expertise spans marketing strategy, customer engagement, brand development, sales enablement, and cross-functional leadership. Known for her empowering leadership style and strategic vision, she consistently builds high-performing teams that drive sustainable business growth while fostering collaboration and innovation.

Her accomplishments include:

Leading global marketing strategy for LHH, integrating brand, demand generation, and customer experience to drive business performance.Guiding enterprise brand transformations and go-to-market strategies across multiple global organizations.Driving measurable growth in pipeline, revenue, and digital engagement through data-driven marketing initiatives.Leading marketing efforts through complex mergers and organizational transformations.Serving as a two-time board chair and lifetime member of Strategic & Competitive Intelligence Professionals.Recognized as a Top Woman in Marketing by PRWeek.

“Melanie’s ability to translate complex market dynamics into clear, impactful strategies, combined with her commitment to building strong, collaborative teams, makes her an exceptional addition to EWA,” said Larraine Segil. “Her leadership and results-driven approach align seamlessly with the values of our sisterhood.”

Melanie shared “I’m honored to be part of the Exceptional Women’s Alliance and look forward to learning from the incredible women leaders who are dedicated to lifting other women and impacting the world at large.”

Siewert now joins a powerful and growing community of C-suite and board-level women leaders across disciplines who share a common goal: to support one another through confidential, life-long mentoring relationships and to enrich both their professional and personal lives.

About Exceptional Women Alliance (EWA)
The Exceptional Women Alliance (EWA) is an invitation-only peer mentorship organization where high-level Exceptional Women from across multiple industries are hand-selected and invested in, to grow, learn, share, and succeed. In addition to the achievement of significant success, the criteria for acceptance include character traits that are defining of the EWA Culture – Kindness, the Spirit of Generosity, Transparency, Gratitude, and Willingness to Share their knowledge. The Foundation is a powerhouse of peer-to-peer mentoring that provides guidance, deep connection, and leadership, propelling each woman to sustainable success—one woman at a time. The life-long program enables each participant to be connected as alumnae in the ever-expanding EWA global community, as their fellow women leaders continue to move into positions of significance.

Learn more at www.exceptionalwomenalliance.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/melanie-siewert-chief-marketing-officer-at-lhh-joins-the-exceptional-women-alliance-ewa-302767205.html

SOURCE Exceptional Women Alliance

Continue Reading

Technology

Insurance Modernization at Risk as Workforce Strategies Fall Behind, Says Info-Tech Research Group

Published

on

By

Insurers are under pressure to modernize core systems while competing for scarce cloud, data, AI, and cybersecurity talent. Info-Tech Research Group’s new blueprint, Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance, outlines a practical framework to help insurance IT and HR leaders assess readiness, strengthen their employee value proposition, and retain the critical roles needed to accelerate transformation.

ARLINGTON, Va., May 8, 2026 /PRNewswire/ – Insurance modernization is increasingly being constrained by the people and capabilities required to deliver it, according to Info-Tech Research Group. The global research and advisory firm’s newly published blueprint, Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance, provides a structured approach to help insurers attract, retain, and mobilize the IT talent required to support digital transformation.

The firm’s research indicates that many insurers are trying to advance core system modernization while facing shortages in cloud, data, AI, and cybersecurity roles. At the same time, experienced legacy system experts are retiring, creating knowledge gaps that can slow delivery, increase operational risk, and deepen dependence on external partners.

“Insurance modernization cannot succeed if the workforce strategy behind it remains outdated,” says Vidhi Trivedi, senior research analyst at Info-Tech Research Group. “Insurers need an employee value proposition that reflects what both digital and legacy talent value today: flexibility, growth, purpose, and belonging. When organizations connect those expectations to the technology roadmap, they are better positioned to retain institutional knowledge, attract new capabilities, and move transformation forward with confidence.”

Key Workforce Risks Slowing Insurance Modernization

Info-Tech’s blueprint identifies several talent challenges that are limiting insurers’ ability to modernize effectively:

Critical digital skills remain difficult to attract and retain. Cloud engineers, data architects, cybersecurity specialists, and AI-capable technologists are essential to future-state systems, integration, and automation.Legacy expertise is leaving faster than it can be replaced. Core system knowledge remains vital to operations, compliance, and transition planning, yet many long-tenured experts are approaching retirement or feel disconnected from future-state roles.Rigid work models reduce access to high-demand talent. Digital professionals increasingly expect hybrid options, autonomy, modern delivery practices, and environments that support productivity and wellbeing.Growth pathways are not clearly connected to transformation needs. Without structured upskilling, internal mobility, and role progression, insurers risk losing employees to industries perceived as more innovative or career-accelerating.Employer branding often undersells insurance’s purpose and impact. The industry plays a critical role in protecting people, businesses, and communities, but that purpose is not always translated into a compelling technology career story.

Info-Tech’s Three-Phase Framework for Rebuilding the Insurance IT Talent Engine

To help insurers address these challenges, the Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint outlines a three-phase methodology:

Assess Talent Readiness for Modernization Success
Insurance IT and HR leaders identify modernization-critical roles, evaluate workforce pressure, assess EVP fit across key roles, and prioritize the roles that pose the greatest risk to transformation timelines.Build and Embed a Modern Employee Value Proposition
Organizations define a clear employer-employee value exchange, establish proof points across the four EVP pillars of flexibility, growth, purpose, and belonging, and activate targeted initiatives for priority roles.Develop and Present the EVP Impact Report
Leaders synthesize workforce insights, visualize progress, and present a measurable view of how EVP activation is improving retention, engagement, internal mobility, and readiness.

The resource also includes supporting tools, such as the EVP Diagnostic Tool, EVP Activation & Implementation Tool, and EVP Impact Report Template, that help insurers move from talent planning to measurable action.

“Too often, insurers view IT talent challenges as a capacity issue, when they are really a transformation risk,” explains Trivedi. ” “The insurers that move fastest will be those that know where critical capabilities are under strain, protect the expertise that increases operational resilience, and create clear pathways for employees to help shape the future of insurance from within.”

By applying Info-Tech’s framework outlined in the Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint, insurance leaders can better understand where people-related risks are highest, strengthen retention in critical roles, reduce long-term reliance on external partners, and build a more resilient technology organization. The firm’s research emphasizes that a modern EVP is not only an HR initiative but a strategic enabler of modernization success.

For exclusive and timely commentary from Info-Tech’s experts, including Vidhi Trivedi, and access to the complete Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/insurance-modernization-at-risk-as-workforce-strategies-fall-behind-says-info-tech-research-group-302767354.html

SOURCE Info-Tech Research Group

Continue Reading

Technology

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

Published

on

By

IRVING, Texas, May 8, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.

Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).

The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality systems, personnel qualifications and compliance with applicable state regulations.

“Caris is committed to meeting the highest standards for laboratory quality, validation and regulatory compliance,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “This submission of Caris Assure for review through the New York State Department of Health’s Wadsworth Center reflects our disciplined approach to expanding access to our technologies in a manner that demonstrates the rigor, responsibility and focus on the patient that define Caris Life Sciences and guide our work in the markets we serve.”

At this time, no determination has been made by NYSDOH, and Caris Assure is not authorized for use on blood-based specimens originating from New York State unless and until CLEP authorization is granted.

Caris operates a CAP-accredited, CLIA‑certified clinical laboratory and performs testing in jurisdictions where it is authorized to do so, in accordance with all applicable federal, state, and local regulations. Any future availability of Caris Assure in New York State will be contingent upon completion of the CLEP review process administered by the Wadsworth Center and receipt of the appropriate authorization.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-submits-application-to-new-york-state-department-of-health-for-caris-assure-bloodbased-testing-authorization-302767104.html

SOURCE Caris Life Sciences

Continue Reading

Trending